I think we'll be seeing the FDA step up their game getting generics out of their inbox. From what I see so far for 2017, they have some catching up to do. Fluticare would be nice to see this summer. INNV should get a nice short term boost imo.
FDA subscription to receive updates if you want them, very helpful if you're playing a lot of different bio's.
"Perfection is not attainable, but if we chase perfection we can catch excellence." Vince Lombardi Do your research! Play the TA. All posts are my opinion.